PROS1 and neoplasm: Further, the ability to distinguish between invasive and indolent tumors remains a long-standing clinical problem in PCa, as monitoring PSA levels is not a reliable indicator of tumor aggression (Mccaffery et al., 2019) and the field lacks well-defined subtypes.